Heart Tronics Inc (HRTT)

[TechKim]

Signalife Presence at XIII World Congress on Cardiac Pacing and
Electrophysiology


STUDIO CITY, CA, December 3, 2007 -- Signalife, Inc. (Amex: SGN - News)
has announced its presence at the XIII World Congress on Cardiac Pacing
and Electrophysiology to be held December 2-6, 2007 in Rome, Italy. At
the Congress, Dr. Muricio Arruda, who has been testing Signalife's
wireless Fidelity 400 Intracardiac Monitor at the Electrophysiology
Laboratories of the Cleveland Clinic Heart Center, will present a
prototoype of the Fidelity 400 Intracardiac Monitor to selected
participants. The Signalife Fidelity 400 Intracardiac Monitor applies
Signalife's award-winning proprietary physiological signal acquisition and
amplification technology to read intracardiac signals procured from
intracardiac catheter products. An intracardiac catheter is a flexible
tube that is inserted through a vein in the leg and fed into the heart.
The catheter is equipped with electrodes which allows the signal to be
recorded within the heart, and the catheter data is transmitted to a
monitor, which allows the physician to evaluate cardiac function,
including arrhythmia, or irregular heartbeat. These readings are
beneficial in that they measure signals directly from the heart, as
opposed to signals read from the surface of the body as is typical in the
ordinary application of heart monitors.
The mission of the World Congress of Cardiac Pacing and Electrophysiology
is to provide an education forum, underlining evidence-based clinical
practices in the field of arrhythmology for clinical cardiologists and
electrophysiologists. The Congress will also highlight the latest and
most advanced topics in invasive electrophysiology and cardiac pacing,
giving leading electrophysiologists the opportunity to demonstrate and
discuss new diagnostic and therapeutic strategies.
Dr. Arruda, a faculty member of the XIII World Congress, stated: "I am
very happy and impressed with the progress made by the Signalife research
& development team on the Fidelity 400 multi- channel, wireless ECG/IC
system from the initial results presented at the 2006 Heart and Rhythm
Society Conference. The main objective and benefit of the novel system is
to offer a technology that overcomes problems presently associated with
recordings of surface ECG and intracardiac signals during
electrophysiological studies".
Dr. Budimir Drakulic, Signalife's Chief Technology Officer, stated: "We
have applied Signalife's patented signal processing technology to
intracardiac signals with the same success realized with ambulatory ECG
recordings and are looking forward to further development of this
technology. We intend to file this one-of-a-kind intra-cardiac monitor
for FDA approval shortly."
Dr Lowell Harmison, Signalife's President, states that "this technology
application will allow us to get new data concerning a host of
electrophysiological changes in the heart that were impossible to be
obtained before. Our electrocardiography technology is opening new
opportunities for medical research and clinical findings based on getting
a more accurate and definitive ECG signal in the catheterization lab and
surgery as well as under conditions of stress and a spectrum of ambulatory
conditions. It is becoming a powerful new tool for cardiac monitoring and
for improved cardiac care."
About Signalife
Signalife, Inc. is a life sciences company focused on the monitoring and
detection of disease through continuous biomedical signal monitoring.
Signalife uses its patented signal technology to design and develop
medical devices that simplify and reduce the costs of diagnostic testing
and patient monitoring in an ambulatory setting.
Signalife is publicly traded on the American Stock Exchange under the
symbol SGN. The website for the company is http://www.Signalife.com. Clear
Data. Trusted Results.
Caution Regarding Forward-Looking Statements
Statements in this release that are not strictly historical are "forward-
looking" statements. Forward-looking statements involve known and unknown
risks, which may cause Signalife's actual results in the future to differ
materially from expected results. Factors which could cause or contribute
to such differences include, but are not limited to, failure to complete
the development and introduction of heart monitoring and other biomedical
devices incorporating Signalife's technology, failure to obtain federal or
state regulatory approvals governing heart monitoring and other biomedical
devices incorporating Signalife's technology, inability to obtain
physician, patient or insurance acceptance of for heart monitoring and
other biomedical incorporating Signalife's technology, and the
unavailability of financing to complete management's plans and objectives,
including the development of heart monitoring and other biomedical
incorporating Signalife's technology. These risks are qualified in their
entirety by cautionary language and risk factors set forth and to be
further described in Signalife's filings with the Securities and Exchange
Commission.